To Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly for Subjects With HER2 Negative Metastatic Breast Cancer

Trial Profile

To Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly for Subjects With HER2 Negative Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 04 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 30 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2017.
    • 24 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top